Inhibrx Advances INBRX-106, Ozekibart Programs, Key Milestones Expected Next Year

Inhibrx is advancing two clinical-stage programs with near-term 2026 catalysts: INBRX-106, an OX40 agonist being tested with Merck’s Keytruda in a phase 2/3 first-line HNSCC trial (46 of 60 patients enrolled; phase 2 enrollment expected to complete in Q1 2026) and a phase 1/2 checkpoint-inhibitor refractory NSCLC cohort that recently hit its 34-patient target; datasets are currently immature but company expects H2 2026 data maturity to assess superiority versus standard of care. Separately, Ozekibart is in a phase 1/2 combo with FOLFIRI in heavily pretreated colorectal cancer with PFS data expected to mature in Q2 2026, and in a combo with IRI/TMZ for relapsed/refractory Ewing sarcoma with enrollment due to complete in Q2 2026 — if response/duration trends hold Inhibrx plans an FDA meeting in H2 2026 to discuss accelerated approval. Shares closed at $81.57, up 7.03%, and the upcoming readouts represent key de‑risking and regulatory inflection points for investors.

Analysis

Inhibrx is advancing two clinical-stage programs with defined near-term catalysts: INBRX-106 (an OX40 agonist) is being evaluated with Merck’s Keytruda in a phase 2/3 first-line trial for unresectable/metastatic HNSCC (46 of 60 patients enrolled; phase 2 enrollment expected to complete in Q1 2026) and in a separate phase 1/2 cohort for checkpoint inhibitor–refractory NSCLC that reached its 34-patient enrollment target. The HNSCC primary endpoint for the phase 2 portion is overall response rate with secondary endpoints including duration of response, progression-free survival and safety; NSCLC endpoints include objective response rate and disease control rate, but the company reports datasets are currently immature.

Inhibrx expects INBRX-106 datasets to mature in the second half of 2026 to inform superiority versus the standard of care. Ozekibart is in a phase 1/2 FOLFIRI combination for heavily pretreated colorectal cancer with progression-free survival data expected to mature in Q2 2026, and a separate IRI/TMZ combination in Ewing sarcoma with enrollment completion expected in Q2 2026; management plans an FDA meeting in H2 2026 for accelerated approval discussion if response and duration trends hold.

Market reaction is sensitive: shares closed at $81.57, up 7.03%, and third-party sentiment is mildly positive (market impact score ~0.35). These upcoming readouts and regulatory interactions are binary de-risking events likely to drive significant price volatility; investors should watch data maturity, primary endpoints and safety readouts as the determinative factors for valuation revisions.

Key Decisions for Investors

• Maintain or establish only a size-limited, speculative position given binary upside from H2/Q2 2026 readouts and the current immaturity of datasets
• Monitor three near-term operational triggers closely: completion of HNSCC phase 2 enrollment in Q1 2026, Ozekibart PFS data maturity in Q2 2026, and enrollment completion/FDA meeting timing for Ewing sarcoma in H2 2026
• Use event-driven risk management such as tight position sizing, predefined stop-losses or option protection ahead of the 2026 data windows to guard against downside from negative or non‑definitive outcomes
• If H2 2026 data show clear superiority or durable responses, consider increasing exposure; if data fail to show efficacy or raise safety concerns, reduce exposure promptly